Kardigan Launches with $300 Million Series A

Kardigan, a company focused on modernizing cardiovascular drug development, has closed a $300 million Series A funding round. The round was led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage.

Kardigan is a biotech company working to improve treatments for heart disease and serves patients with cardiovascular conditions who may not respond well to existing therapies. The company focuses on developing targeted treatments for conditions such as primary and secondary cardiomyopathies and heart failure, using research, data-sharing, and acquisitions to accelerate drug development. Kardigan’s research and drug development efforts also support cardiologists, hospitals, and healthcare providers seeking advanced treatments for heart failure and related conditions.

Kardigan, led by CEO Tassos Gianakakos, is headquartered in South San Francisco, California, and Princeton, New Jersey.

“For decades, our team has observed significant treatment gaps across cardiovascular disease—from clinical care to investment in new medicines. While current standards of care play an important role, collectively, they fail to address the global health emergency in front of us,” said Mr. Gianakakos. “At Kardigan, we are bringing together a world-class team of experts to think differently with a singular focus to deliver multiple important medicines at an unprecedented rate. Our cardiac intelligence model enables our teams to generate and share data across Kardigan’s programs, increasing our efficiency and probability of success in each of our late-stage programs that were carefully curated to advance our mission.”

Perceptive Advisors, headquartered in New York City, is a healthcare-focused investment firm that invests in biotech and life sciences companies.

ARCH Venture Partners, based in Chicago, focuses on early-stage investments in life sciences, physical sciences, and technology companies.

Sequoia Heritage, headquartered in Menlo Park, is an investment fund affiliated with Sequoia Capital that specializes in long-term investments in high-growth sectors, including healthcare and life sciences.